DRUG INFORMATION journal

OFFICIAL PUBLICATION OF THE DRUG INFORMATION ASSOCIATION

VOL
12
197

ALBERTA D. BERTON

Editor

VOLUME 12, 1978

DRUG INFORMATION journal

OFFICIAL PUBLICATION OF THE DRUG INFORMATION ASSOCIATION

VOL
12
197

ALBERTA D. BERTON

Editor

VOLUME 12, 1978

MEMBERSHIP in the DRUG INFORMATION ASSOCIATION, INC. is open to those who are concerned in any way with drug information. The annual membership fee is $20.00 and includes a subscription to the DRUG INFORMATION JOURNAL.

SUBSCRIPTION rate of the DRUG INFORMATION JOURNAL is $15.00 U.S. $20.00 Foreign per year (quarterly). Special issues individually priced. Subscription payments and changes of address should be sent to the BUSINESS OFFICE
Drug Information Association
1050 George Street
Apartment 5L
New Brunswick, NJ 08901

THE DRUG INFORMATION JOURNAL is published two to four times a year at Philadelphia, Pennsylvania, by the DRUG INFORMATION ASSOCIATION, INC. Third Class postage paid at the post office at Philadelphia, Pennsylvania. Composition by THE MEDICAL DOCUMENTATION SERVICE of the College of Physicians, 19 South 22nd Street, Philadelphia, Pennsylvania 19103.

ONLY a limited number of contributions to the DRUG INFORMATION JOURNAL can be accepted. These are subject to review by the Editorial Advisory Board. Manuscripts should be typewritten double-spaced, on one side of 8½ x 11" sheets of bond paper. Two carbon copies should be submitted, in addition to the original. Pages of the manuscript, including tables but not figures, should be numbered consecutively. An original drawing of figures and two copies should be submitted. An informative abstract of 100 to 300 words should be submitted with each article. Citations to the literature should follow the style: Orne, J.: Resources of Foreign Scientific Literature: Acquisition on a National Scale, *Am. Doc. 14:229-233* (July) 1963.
The DRUG INFORMATION ASSOCIATION, INC. assumes no responsibility for statements and opinions advanced by contributors to the DRUG INFORMATION JOURNAL. Views expressed in editorials are those of the writer and do not necessarily represent the official opinion of the DRUG INFORMATION ASSOCIATION, INC.

Copyright 1978 by the
DRUG INFORMATION ASSOCIATION, INC.

PUBLISHER
Drug Information Association, Inc.
EDITOR
Alberta D. Berton
ASSOCIATE EDITOR
Harriet E. Rockwell
EDITORIAL ASSISTANT
and ADVERTISING MANAGER
K. Bernice Odom

EDITORIAL OFFICE
Medical Documentation Service
College of Physicians
19 S. 22nd Street
Philadelphia, Pa. 19103
Telephone (215) 563-1238

DRUG INFORMATION journal

Volume 12 Number 1 January/March 1978

5 Drug information requirements of recently graduated professional nurses.
Riley, I.K.
8 Drug information in diploma nursing education.
Carter, S.
11 Drug information in pharmacy education.
Rosman, A.W. and Romano, J.A.
15 The pharmaceutical manufacturers representative.
Roustan, P.T.
20 Drug information and pharmaceutical quality control.
Stroud, R.R.
23 Quality assurance of drugs — the QUAD program.
Leclerc-Chevalier, D.
26 Proposed government role in drug information.
Spino, M.
29 Preliminary design for a comprehensive data system for drug information.
Berkowitz, S.D. and Chang, E.
33 Government and drug information — FDA.
Groth, P. E.
37 Government as coordinator of drug information.
Philbrook, F.
40 Drug information risks under the Freedom of Information Act.
Cuddihy, R.V.
45 New direction in OTC drug labeling.
Kerner, G.H.
51 CPS and government.
Rotenberg, G.N.

(Continued on next page)

53 Should government be the developer and disseminator of drug-use information?
Johnson, K.W.
56 Information sources—American Society of Hospital Pharmacists.
Tousignaut, D.R.
59 Official written patient drug-use information.
Heller, W.M.
63 The professional organization as an information source.
Francke, G.N.
65 Intrauterine contraception information for the patient.
Benson, H. and Place, V.
70 Device information and government regulations.
Desjardins, J.-P.
72 The future of medical device information.
Harper, J.D.

INSTRUCTIONS FOR CONTRIBUTORS

All papers submitted to the Journal Editor for publication must be submitted in triplicate and will be scheduled according to receipt date, and closing dates necessary to meet the quarterly publishing schedule. It is requested that all material be submitted with good legible copy - and in any case where Figures or Tables are a part of the paper, it is absolutely necessary for the quality of the journal and to add to the quality of your own submission, that they be submitted in copy ready for publication (original if at all possible - not poor quality xerox, which makes reproduction almost impossible). Tables submitted should be in format to fit single column or double column measurements, namely no wider than 3⅜" for single column and 6⅞" for double column format. Unless the nature of the artwork is such that reduction is mandatory, we would like to avoid additional costs in re-typesetting procedures.

Manuscripts themselves should be typewritten, double-spaced, on one side of 8½" X 11" paper. Pages of the manuscript should be numbered consecutively. Please use Arabic numbers for tables and figures. Drawings should be submitted in the original form to facilitate better reproduction. Citations to the literature should follow Z-39 standards.

Upon receipt in the Editorial Office, the paper will be submitted to two members of the Editorial Board for review. Upon receipt of the paper you will be notified of its arrival, upon acceptance, the author will be notified of the approximate date for inclusion in the Journal. Notification of the paper's acceptance will also include a listing of the cost for preprints, and if orders are received prior to publication date, considerable saving for preprints over later reprinting will be realized by the author.

Papers will not be returned to the author after editing and typography, because of delays created by this practice in final publication date. However, should any serious editorialization seem necessary, which might in some way change the concept of the paper, the author will be contacted for final discussion regarding the point at issue.

All members of the Editorial Board are requested to return the paper submitted to them for review within one month of receipt. If the paper has not been returned to this office within this time schedule, it will be editorialized and published in order to avoid delays in release of the issue, and to permit timeliness of publication. Members of the Editorial Board are requested **not** to edit the paper (which procedure will be done by the Editor), but to submit an evaluation of the paper as a guide to acceptance for publication.

If there are any questions or inquiries at any time with regard to your submission, your Editor will more than welcome your contacting the Editorial Office.

ALBERTA D. BERTON, Editor

VOL
12
197

L.
78

MEMBERSHIP in the DRUG INFORMATION ASSOCIATION, INC. is open to those who are concerned in any way with drug information. The annual membership fee is $20.00 and includes a subscription to the DRUG INFORMATION JOURNAL.

SUBSCRIPTION rate of the DRUG INFORMATION JOURNAL is $15.00 U.S. $20.00 Foreign per year (quarterly). Special issues individually priced. Subscription payments and changes of address should be sent to the BUSINESS OFFICE
Drug Information Association
1050 George Street
Apartment 5L
New Brunswick, NJ 08901

THE DRUG INFORMATION JOURNAL is published two to four times a year at Philadelphia, Pennsylvania, by the DRUG INFORMATION ASSOCIATION, INC. Third Class postage paid at the post office at Philadelphia, Pennsylvania. Composition by THE MEDICAL DOCUMENTATION SERVICE of the College of Physicians, 19 South 22nd Street, Philadelphia, Pennsylvania 19103.

ONLY a limited number of contributions to the DRUG INFORMATION JOURNAL can be accepted. These are subject to review by the Editorial Advisory Board. Manuscripts should be typewritten double-spaced, on one side of 8½ x 11" sheets of bond paper. Two carbon copies should be submitted, in addition to the original. Pages of the manuscript, including tables but not figures, should be numbered consecutively. An original drawing of figures and two copies should be submitted. An informative abstract of 100 to 300 words should be submitted with each article. Citations to the literature should follow the style: Orne, J.: Resources of Foreign Scientific Literature: Acquisition on a National Scale, *Am. Doc. 14:229-233* (July) 1963.

The DRUG INFORMATION ASSOCIATION, INC. assumes no responsibility for statements and opinions advanced by contributors to the DRUG INFORMATION JOURNAL. Views expressed in editorials are those of the writer and do not necessarily represent the official opinion of the DRUG INFORMATION ASSOCIATION, INC.

Copyright 1978 by the
DRUG INFORMATION ASSOCIATION, INC.

PUBLISHER
Drug Information Association, Inc.
EDITOR
Alberta D. Berton
EDITORIAL ASSISTANT
and ADVERTISING MANAGER
K. Bernice Odom

EDITORIAL OFFICE
Medical Documentation Service
College of Physicians
19 S. 22nd Street
Philadelphia, Pa. 19103
Telephone (215) 563-1238

DRUG INFORMATION journal

Volume 12 Number 3 July/September 1978

133 Microfiche submissions for original new drug applications.
Gring, I.H. and Kester, G.T.
137 Is medical truth legal?
Ryan, M.F. and Magnani, J.L.
141 A computer system and statistical methodology for the analysis of blood and urine chemistry data in laboratory animals.
Bare, J.J., Janakiraman, T., Phillips, B.M., Platt, R.D. and Whitesell, Jr., J.H.
153 A new focus on clinical data entry, widening the scope to the clinical environment.
Gitomer, S.L.
157 Clinical research: the obligation of the investigator, the sponsor, and the monitor.
Guarino, R.A.
160 FDA's consumer education and information programs.
Guinan, J.O.
163 Drug information utilization — the need for government/industry communications.
Gelberg, A.
167 The *Federal Register*, FDA, and you.
Emery, F.J.
170 What's current in canadian device regulations?
DasGupta, A.K.
174 An interactive pathology/toxicology computer system.
Kellenbenz, A., Mosher, A.H., Teal, T.W. and Crocco, R.M.
181 Proposed legislation — its impact on drug information processing.
Cleveland, C.B. and Adams, J.
185 What's current in U.S. device regulations?
Butts, H.E.

• • • • • •

169 Letter to the editor.
de Haen, P.

MEMBERSHIP in the DRUG INFORMATION ASSOCIATION, INC. is open to those who are concerned in any way with drug information. The annual membership fee is $20.00 and includes a subscription to the DRUG INFORMATION JOURNAL.

SUBSCRIPTION rate of the DRUG INFORMATION JOURNAL is $15.00 U.S. $20.00 Foreign per year (quarterly). Special issues individually priced. Subscription payments and changes of address should be sent to the BUSINESS OFFICE
Drug Information Association
1050 George Street
Apartment 5L
New Brunswick, NJ 08901

THE DRUG INFORMATION JOURNAL is published two to four times a year at Philadelphia, Pennsylvania, by the DRUG INFORMATION ASSOCIATION, INC. Third Class postage paid at the post office at Philadelphia, Pennsylvania. Composition by THE MEDICAL DOCUMENTATION SERVICE of the College of Physicians, 19 South 22nd Street, Philadelphia, Pennsylvania 19103.

DL.
2
978

ONLY a limited number of contributions to the DRUG INFORMATION JOURNAL can be accepted. These are subject to review by the Editorial Advisory Board. Manuscripts should be typewritten double-spaced, on one side of 8½ x 11" sheets of bond paper. Two carbon copies should be submitted, in addition to the original. Pages of the manuscript, including tables but not figures, should be numbered consecutively. An original drawing of figures and two copies should be submitted. An informative abstract of 100 to 300 words should be submitted with each article. Citations to the literature should follow the style: Orne, J.: Resources of Foreign Scientific Literature: Acquisition on a National Scale, *Am. Doc. 14:229-233* (July) 1963.

The DRUG INFORMATION ASSOCIATION, INC. assumes no responsibility for statements and opinions advanced by contributors to the DRUG INFORMATION JOURNAL. Views expressed in editorials are those of the writer and do not necessarily represent the official opinion of the DRUG INFORMATION ASSOCIATION, INC.

Copyright 1978 by the
DRUG INFORMATION ASSOCIATION, INC.

PUBLISHER
Drug Information Association, Inc.
EDITOR
Alberta D. Berton
EDITORIAL ASSISTANT
and ADVERTISING MANAGER
K. Bernice Odom

EDITORIAL OFFICE
Medical Documentation Service
College of Physicians
19 S. 22nd Street
Philadelphia, Pa. 19103
Telephone (215) 563-1238

DRUG INFORMATION journal

Volume 12 Number 4 October/December 1978

191 Editorial- - A tribute to Donald E. Francke (1910-1978).
Tousignaut, D. R.
193 Intraocular lenses: Problems regarding their use and regulation.
Spaeth, G. L.
197 What's current in U.S. drug regulation.
Halperin, J. A.
204 Compliance activities and experience with FDA good laboratory practice inspection.
Kirsch, T. J.
211 What's current in international drug and device regulations.
Kerner, G. H.
216 Development of a documentation system for a drug with unusual and ubiquitous clinical applications: PARLODEL.®
Dittmer, I. A. K.
219 Computer selection — a case history.
Olson, E. C., Duchamp, D. J., Zieserl, J. F., Aldrich, J. B. and Kenny, M. D.
225 An on-line data base for toxicology studies for a small pharmaceutical company.
Kratochwill, B., Caton, J. M. and Benson, H.
230 Merck preclinical system development in a GLP environment.
Jogwick, F. H., Drew, R. T., Greenberg, W. P. and Fleishman, P. S.

. . . . . .

218 Letter to the editor.
229 Errata

. . . . . .

235 Index- - volume 12, 1978.

VO
12
19

SUBJECT INDEX

The Author and Subject indexes were provided by the American Society of Hospital Pharmacists through its computerized IPA Information System.

The reference numbers are the first page number of an article followed by the year of publication.

In the Author index an "S" following the year - e.g., "15(1977)S" - indicates that the reference is in the supplement issue published that year. The "S" does not appear in the Subject index and therefore references to pages 1 through 79 for 1977 may be to the supplement or to issues 1 and 2. This applies only to the year 1977.

A

Administration
clinical studies; computers, user oriented modular research data management system, 98(1978)
policies and procedures; McNeil Labs, Good Laboratory Practices manual, 204(1978)
purchasing; computers, selection, guidelines, for automated drug analysis lab, 219(1978)
Adverse drug reactions, see **Drugs, adverse reactions**
Advertising
drug information; restrictions, FDA regulations, 137(1978)
drugs; regulations, government role, Canada, 37(1978)
drugs, over-the-counter; regulations, discussion, 45(1978)
AIRES; drug information; toxicology, ALZA online data base, 225(1978)
American Pharmaceutical Association; Pharmacy Intelligence Center; role, drug information source, 63(1978)
American Society of Hospital Pharmacists; drug information; publications, 56(1978)
Analysis
automation; computers, selection, 219(1978); laboratories, animal, blood and urine chemistry data, Miles Lab, 141(1978)
information; Canada, QUAD program, 23(1978)
Anti-arrhythmic agents, see **Cardiac drugs**
Apparatus, see **Equipment**
Associations, see **Organizations**
Automation, data processing, computers
AIRES; drug information, toxicology, ALZA online data base, 225(1978)
analysis; animals, laboratory, blood and urine chemistry data, Miles Lab system, 141(1978)
clinical studies; information, clinical data entry, Marion Labs, 153(1978); information, international, CRISS system, 92(1978); information, user oriented modular research data management system, 98(1978)
drug information; animals, clinical pathology and toxicology data, 230(1978); Canada, proposed integrated national data storage and retrieval system, 29(1978); toxicity, and pathology, McNeil Labs, 174(1978)
purchasing; selection, recommendations, drug analysis lab, 219(1978)
toxicity; information, indexing and retrieval system for tests, 85(1978)
Availability; drugs, see **Drugs, availability**

B

Bioavailability, see **Drugs, availability**
Bromocriptine; information; Sandoz, documentation system, 216(1978)

C

Canada
Compendium of Pharmaceuticals and Specialties; role, drug information, 51(1978)
devices; information, regulations, pharmacists role in providing information, 70(1978); regulations, discussion, 170(1978); regulations, government role, 72(1978)
drug information; costs, proposed government funding for patient information, 26(1978); national, integrated data storage and retrieval system, 29(1978); role, government, 37(1978); sources, QUAD program, 23(1978)
representatives, pharmaceutical; education, requirements, 15(1978)
Canadian Pharmaceutical Manufacturers Association; representatives, pharmaceutical; education, requirements, 15(1978)
Cardiac drugs; propranolol hydrochloride; information, restricted, on new use, 137(1978)
Cataract extraction; and intraocular lenses; regulations, and clinical trials, 193(1978)
Chemistry; drug information; sources, pharmacy industry, 20(1978)
Classification; drugs, investigational; regulations, FDA system, 197(1978)
Clinical pharmacy; drug information; education, University of Buffalo School of Pharmacy, 11(1978)
Clinical studies
information; computers, system for clinical data entry, Marion Labs, 153(1978); computers, user oriented modular research data management system, 98(1978); international, CRISS system, 92(1978)
research; role, investigators and monitors, responsibility, 153(1978)
Clinical trials; intraocular lenses; regulations, FDA Advisory Ophthalmic Panel, 193(1978)
Compendia; Drug Regulation Reform Act of 1978; role, discussion, 181(1978)
Compendium of Pharmaceuticals and Specialities
drug information; dentists, use, 81(1978); role, Canada, 51(1978)
Computers, see **Automation, data processing, computers**
Consumers; education; programs, FDA, 160(1978)
Contraceptives, intrauterine devices
information; Canada, pharmacists role, 70(1978)
package inserts; patients, FDA, comparison industry, 65(1978)
Control, quality; Canada; government, role, 37(1978)
Convalescent aids, see **Surgical supplies**
Costs
drug information; publications, proposed Canadian government funding for patient information, 26(1978); toxicology, AIRES, ALZA online data base, 225(1978)
microfiche; new drug applications, FDA submissions, Merck, 133(1978)
CRISS; clinical studies; information, international, 92(1978)

D

Dentists; drug information; sources, 81(1978)
Detail men, see **Representatives, pharmaceutical**
Devices
information; sources, FDA, 33(1978)
intraocular lenses; regulations, FDA Advisory Ophthalmic Panel, 193(1978)
regulations; Canada, discussion, 170(1978); Canada, government role, 72(1978); 1976-1978, discussion, 185(1978); international, overview, 211(1978)
Drug analysis, see **Analysis**
Drug information
AIRES; toxicology, ALZA online data base, 225(1978)
American Pharmaceutical Association; role, Pharmacy Intelligence Center, 63(1978)
American Society of Hospital Pharmacists; publications, 56(1978)
bromocriptine; Sandoz, documentation system, 216(1978)
Canada; national, integrated data storage and retrieval system, 29(1978); role, government, 37(1978); sources, QUAD program, 23(1978)
clinical studies; computers, system for clinical data entry, Marion Labs, 153(1978)
Compendium of Pharmaceuticals and Specialties; role, and relation to Canadian regulations, 51(1978)
consumers; programs, FDA, 160(1978)
contraceptives, intrauterine devices; package inserts, FDA, comparison, industry, 65(1978); role, pharmacists, Canada, 70(1978)
dentists; sources, 81(1978)
devices; Canada, government role, 72(1978)
Drug Regulation Reform Act of 1978; effects, discussion, 181(1978)
drugs, over-the-counter; regulations, discussion, 45(1978)
education; University of Buffalo School of Pharmacy, 11(1978)
Federal Register; role, 167(1978)
Food and Drug Administration (U.S.); methods, dissemination, 33(1978)
Francke, D. E.; history, role, 1(1978)
Freedom of Information Act; effects, 40(1978)
government; role, 53(1978)
industry, pharmaceutical; and FDA, communication systems, 163(1978); sources, chemistry, 20(1978)
labeling; regulations, O-T-C, 45(1978)
nurses; pharmacology, 8(1978); sources, 5(1978)
package inserts; patients, proposed USP role in development, 59(1978)
regulations; restrictions, 137(1978)
toxicity; and pathology, computer system, McNeil Labs, 174(1978); computers, clinical pathology and toxicology data base system, 230(1978); tests, computer based indexing and retrieval system described, 85(1978)
Drug Regulation Reform Act of 1978; drug information; discussion, 181(1978)
Drugs
costs, see **Costs**
new; statistics, from FDA drug classification system, 197(1978)
nonprescription, see **Drugs, over-the-counter**
over-the-counter, see **Drugs, over-the-counter**
research, see **Research**
Drugs, adverse reactions
see also **Toxicity**
monitoring; programs, FDA postmarketing surveillance, 197(1978)
Drugs, availability; information; sources, Canada, QUAD program, 23(1978)
Drugs, clinical effectiveness; Information; effects, Drug Regulation Reform Act of 1978, 181(1978)
Drugs, investigational
investigational new drugs; classification, FDA system, 197(1978)
new drug applications; classification, FDA system, 197(1978); information, obligations of investigator, sponsor and monitor, 153(1978); microfiche, FDA submissions, costs, Merck, 133(1978)
Drugs, over-the-counter
labeling; regulations, discussion, 45(1978)
regulations; international, overview, 211(1978)

E

Economics; drug information; Canada, proposed national integrated drug storage and retrieval system, 29(1978)
Education
consumers; programs, FDA, 160(1978)
nursing; pharmacology, drug information, 8(1978)
Education, pharmaceutical
drug information; University of Buffalo Schol of Pharmacy, 11(1978)
representatives, pharmaceutical; Canada, requirements, 15(1978)
Equipment; computers; selection, guidelines, for automated drug analysis lab, 219(1978)
Equivalency, generic; regulations; substitution, FDA therapeutic equivalence list, 197(1978)
Excretion; drugs; information, computer system, animals, Miles Lab, 141(1978)

F

FDA, see **Food and Drug Administration (U.S.)**
Federal Register; drug information; role, 167(1978); drugs, over-the-counter; regulations, discussions, 45(1978)
Food and Drug Administration (U.S.)
clinical studies; role, investigator, sponsor and monitor, 153(1978)
drug information; description, communication with regulated industries, 163(1978); methods, dissemination, 33(1978); regulations, restrictions, 137(1978)
education; consumers, programs, 160(1978)
Freedom of Information Act; effects, drug information, 40(1978)
Good Laboratory Practices; policies and procedures, McNeil Labs, 204(1978)
intraocular lenses; regulations, 193(1978)
package inserts; contraceptives, intrauterine devices, comparison, industry and FDA inserts, 65(1978)
Francke, D. E.; history; role, drug information and hospital pharmacy, 1(1978)
Freedom of Information Act; drug information; effects, FDA, 40(1978)

G

Good Laboratory Practices; industry, pharmaceutical; policies and procedures, McNeil Labs, 204(1978)

H

Health care; information; publications, proposed Canadian government funding for patient information, 26(1978)
History; Francke, D. E.; role, drug information and hospital pharmacy, 1(1978)
Hospital pharmacy, see **Pharmacy, institutional, hospital**

I

IND, see **Drugs, investigational;** investigational new drugs
Indexing; bromocriptine; Sandoz, documentation system, 216(1978)
Industry; computers; criteria, for selecting system for automated drug analysis use, 219(1978)
Industry, pharmaceutical
Canada; information, QUAD program, 23(1978)
clinical studies; research, role of the investigator, 153(1978)
computers; AIRES, toxicology, ALZA online data base, 225(1978)
drug information; description, FDA communication systems, 163(1978); sources, chemistry, 20(1978)
Good Laboratory Practices; policies and procedures, McNeil Labs, 204(1978)
package inserts; contraceptives, intrauterine devices, comparison of FDA and industry prepared insert, 65(1978)
representatives, pharmaceutical; education, requirements, 15(1978)
Information
clinical studies; computers, user oriented modular research data management system, 98(1978)
drugs, see **Drug information**
intraocular lenses; clinical trials, reporting by ophthalmologists, 193(1978)
patients, see **Patient information**
surgical supplies; Canada, pharmacist's role, 70(1978)
Inserts; package, see **Package inserts**
Inspectors; Good Laboratory Practices; policies and procedures, McNeil Labs, 204(1978)
Institutional pharmacy practice, see **Pharmacy, institutional, hospital**
Intraocular lenses; regulations; and clinical trials, FDA Advisory Ophthalmic Panel, 193(1978)
Intrauterine contraceptive devices, see **Contraceptives, intrauterine devices**
Investigational drugs, see **Drugs, investigational**
IUD, see **Contraceptives, intrauterine devices**

AUTHOR INDEX

A

Adams, J. see Cleveland, C. B., 181
Adornato, F. A. see Snoddy, C. S., 92
Aldrich, J. B. see Olson, E. C., 219

B

Bare, J. J. Computer system and methodology for the analysis of blood and urine chemistry data in laboratory animals, 141(1978)
Benson, H. Intrauterine contraception information for the patient, 65(1978)
Benson, H. see also Kratochwill, B., 225
Berkowitz, S. D. Preliminary design for a comprehensive data system for drug information, 29(1978)
Bird, L. see Sher, S. P., 85
Butts, H. E. What's current in U.S. device regulations?, 185(1978)

C

Carter, S. Drug information in diploma nursing education, 8(1978)
Caton, J. M. see Kratochwill, B., 225
Chang, E. see Berkowitz, S. D., 29
Cleveland, C. B. Proposed legislation—its impact on drug information processing, 181(1978)
Crocco, R. M. see Kellenbenz, A., 174
Cuddihy, R. V. Drug information risks under the Freedom of Information Act, 40(1978)

D

DasGupta, A. K. What's current in Canadian device regulations?, 170(1978)
Desjardins, J. P. Device information and government regulations, 70(1978)
Dittmer, I. A. K. Development of a documentation system for a drug with unusual and ubiquitous clinical applications: Parlodel, 216(1978)
Drew, R. T. see Jogwick, F. H., 230
Drew, R. T. see Sher, S. P., 85
Duchamp, D. J. see Olson, E. C., 219

E

Emery, F. J. Federal Register, FDA, and you, 167(1978)

F

Fleishman, P. S. see Jogwick, F. H., 230
Francke, G. N. Professional organization as an information source, 63(1978)

G

Gelberg, A. Drug information utilization—the need for government/industry communications, 163(1978)
Gitomer, S. L. New focus on clinical data entry, widening the scope to the clinical environment, 153(1978)
Greenberg, W. P. see Jogwick, F. H., 230
Gring, I. H. Microfiche submissions for original New Drug Applications, 133(1978)
Groth, P. E. Government and drug information—the FDA, 33(1978)
Guarino, R. A. Clinical research: the obligation of the investigator, the sponsor, and the monitor, 157 (1978)
Guinan, J. O. FDA's consumer education and information programs, 160(1978)

H

Halperin, J. A. What's current in U.S. drug regulation, 197(1978)
Harper, J. D. Future of medical device information, 72(1978)
Heller, W. M. Official written patient drug use information, 59(1978)

J

Jackson, D. K. see Snoddy, C. S., 92
Janakiraman, T. see Bare, J. J., 141
Jogwick, F. H. Merck preclinical system development in a GLP environment, 230(1978)
Johnson, K. W. Should government be the developer and disseminator of drug use information?, 53(1978)

K

Kellenbenz, A. Interactive pathology/toxicity computer system, 174(1978)
Kenny, M. D. see Olson, E. C., 219
Kerner, G. H. What's current in international drug and device regulations, 211(1978)
Kerner, G. H. New directions in OTC drug labeling, 45(1978)
Kester, G. T. see Gring, I. H., 133
Kirsch, T. J. Compliance activities and experience with FDA Good Laboratory Practice inspection, 204(1978)
Kratochwill, B. Online data base for toxicology studies for a small pharmaceutical company, 225(1978)

L

Leclerc-Chevalier, D. Quality assurance of drugs—QUAD program, 23(1978)

M

Magnani, J. L. see Ryan, M. F., 137
Mosher, A. H. see Kellenbenz, A., 174

O

Olson, E. C. Computer selection—case history, 219(1978)

P

Parker, W. A. Dentist attitudes toward drug information resources, 81(1978)
Paul, R. see Sher, S. P., 85
Pecore, V. J. see Snoddy, C. S., 92
Philbrook, F. Government as coordinator of drug information, 37(1978)
Phillips, B. M. see Bare, J. J., 141
Place, V. see Benson, H., 65
Platt, R. D. see Bare, J. J., 141

R

Reid, L. W. see Parker, W. A., 81
Riley, I. K. Drug information requirements of recently graduated professional nurses, 5(1978)
Romano, J. A. see Rosman, A. W., 11
Rosman, A. W. Drug information in pharmacy education, 11(1978)
Rotenberg, G. N. CPS and government, 51(1978)
Roustan, P. T. Pharmaceutical manufacturers representative, 15(1978)
Ryan, M. F. Is medical truth legal?, 137(1978)

S

Sher, S. P. Toxicity test registry: a computer based indexing and retrieval system, 85(1978)
Snoddy, C. S. Clinical research—international simulation system (CRISS), 92(1978)
Spaeth, G. L. Intraocular lenses: problems regarding their use and regulation, 193(1978)
Spino, M. Proposed government role in drug information, 26(1978)
Stitt, F. W. Clinical research data management and analysis—a physician's view, 98(1978)
Stroud, R. R. Drug information and pharmaceutical quality control, 20(1978)

T

Teal, T. W. see Kellenbenz, A., 174
Tousignaut, D. R. Tribute to Donald E. Francke (1910-1978), 1(1978)
Tousignaut, D. R. Information sources—American Society of Hospital Pharmacists, 56(1978)

W

Whitesell, J. H. see Bare, J. J., 141

Z

Zieserl, J. F. see Olson, E. C., 219

L

Labeling; devices; Canada, regulations, discussion, 170(1978)
Laws
see also **Regulations**
drug information; Freedom of Information Act, 40(1978)
Legislation
see **Laws**
see **Regulations**
Legislation, laws and regulations
see **Laws**
see **Regulations**

M

Management, see **Administration**
Metabolism; excretion, see **Excretion**
Methodology
clinical studies; international, information, CRISS system, 92(1978); regulations, role of investigator, sponsor and monitor, 153(1978)
Microfiche; new drug applications; costs, FDA submissions, Merck, 133(1978)

N

NDA, see **Drugs, investigational;** new drug applications
New drug applications, see **Drugs, investigational;** new drug applications
Nurses
drug information; pharmacology, 8(1978); sources, 5(1978)

O

Organizations; standards; devices, international, listing, 211(1978)
O-T-C drugs, see **Drugs, over-the-counter**
Over-the-counter drugs, see **Drugs, over-the-counter**

P

Package inserts
patients; contraceptives, intrauterine devices, FDA, comparison, industry, 65(1978); effects, Drug Regulation Reform Act of 1978, 181(1978); role, USP development, 59(1978)
regulations; discussion, O-T-C labeling, 45(1978)
Parlodel, see **Bromocriptine**
Pathology; information; computers, system, McNeil Labs, 174(1978)
Patient information
Canada; costs, proposed government funding of publications, 26(1978)
package inserts; contraceptives, intrauterine devices, FDA, comparison, industry, 65(1978); effects, Drug Regulation Reform Act of 1978, 181(1978); regulations, discussion, 45(1978); role, USP development, 59(1978)
Pharmaceutical education, see **Education, pharmaceutical**
Pharmaceutical industry, see **Industry, pharmaceutical**
Pharmaceutical representatives, see **Representatives, pharmaceutical**
Pharmacists; drug information; evaluations, by dentists, 81(1978)
Pharmacology; drug information; nurses, 8(1978)
Pharmacopeias; United States, see **United States Pharmacopeia**
Pharmacy
clinical, see **Clinical pharmacy**
education, see **Education, pharmaceutical**
Pharmacy, institutional, hospital; Francke, D. E.; history, role, 1(1978)
Physicians; clinical studies; information, computers, user oriented modular research data management system, 98(1978)
Physiological availability, see **Drugs, availability**
Policies and procedures, see **Administration**
Prescriptions; accessories, see **Surgical supplies**
Propranolol hydrochloride; drug information; restrictions, FDA, on new use, 137(1978)
Publications
drug information; Canada, proposed government funding for patient information, 26(1978); sources, ASHP, 56(1978)
Federal Register; drug information, role, 167(1978)
Purchasing; computers; selection, for automated drug analysis lab, 219(1978)

Q

QUAD, see **Quality Assessment of Drugs**
Quality Assessment of Drugs; drug information; sources, 23(1978)
Quality control, see **Control, quality**

R

Recalls; devices; Canada, regulations, discussion, 170(1978)
Regulations
see also **Laws**
Canada; drug information, role of Compendium of Pharmaceuticals and Specialties, 51(1978)
clinical studies; role, investigator, sponsor and monitor, 153(1978)
devices; Canada, discussion, 170(1978); Canada, government role, 72(1978); 1976-1978, discussion, 185(1978); information, pharmacists role, 70(1978); international, overview, 211(1978)
drug information; Canada, government role, 37(1978); government, role in development and dissemination of drug use information, 53(1978); restrictions, 137(1978); use, computer system for providing pathology/toxicology data, McNeil Labs, 174(1978)
Drug Regulation Reform Act of 1978; effects, drug information, 181(1978)
drugs; and information transfer between FDA and regulated industries, 163(1978); international, overview, 211(1978)
drugs, investigational; classification, FDA system, 197(1978)
Good Laboratory Practices; policies and procedures, McNeil Labs, 204(1978)
intraocular lenses; clinical trials, FDA Advisory Ophthalmic Panel, 193(1978)
labeling; drugs, over-the-counter, 45(1978)
new drug applications; microfiche, for NDA submissions, costs, Merck, 133(1978)
toxicology; information, from AIRES, ALZA online data base, 225(1978)
Representatives, pharmaceutical; Canada; education, requirements, 15(1978)
Research
animals; computers, system for analysis of blood and urine chemistry data, Miles Lab, 141(1978); toxicity, clinical pathology and toxicology data base system, 230(1978)
clinical studies; information, computers, user oriented modular research data management system, 98(1978); information, international, computerized CRISS system, 92(1978); role, investigators and monitors, responsibility, 153(1978)
computers; use, pathology/toxicology, McNeil Labs, 174(1978)
devices; Canada, regulations, discussion, 170(1978)
drugs; new, statistics, FDA classification system, 197(1978)

S

Side effects, see **Toxicity**
Societies, see **Organizations**
Sociology, economics and ethics, see **Economics**
Standards; devices; organizations, listing, international, 211(1978)
Statistics; drugs; new, FDA classification system, 197(1978)
Substitution; equivalency; lists, FDA therapeutic equivalence list, 197(1978)
Supplies; surgical, see **Surgical supplies**
Surgical supplies; information; role, pharmacists, Canada, 70(1978)

T

Therapeutic efficacy, see **Drugs, clinical effectiveness**
Therapeutic equivalent, see **Drugs, clinical effectiveness**
Toxicity
see also **Drugs, adverse reactions**
devices; Canada, regulations, discussion, 170(1978)
information; AIRES, ALZA online data base, 225(1978); computers, clinical pathology and toxicology data, 230(1978); computers, indexing and retrieval system described, 85(1978); computers, system for the analysis of animal blood and chemistry data, Miles Lab, 141(1978); computers, system, McNeil Labs, 174(1978); effects, Drug Regulation Reform Act of 1978, 181(1978)
Training, see **Education**

U

United States Pharmacopeia; package inserts; patients, USP development proposal, 59(1978)

VOL
12
197

L.
78